Braveheart Bio, Inc. SCHEDULE 13D/A filed 2026-09-10

Braveheart Bio, Inc. is the subject of a SCHEDULE 13D/A filed on 2026-09-10 under accession number 0000947871-26-000860. A Schedule 13D is the disclosure a beneficial owner of more than five percent of a company's stock files about its position, and the /A marks this as an amendment. The excerpt available identifies it as Amendment No. 1 to a Statement on Schedule 13D dated September 8, 2026, concerning the common stock of Braveheart Bio, Inc. The portion of the filing shown here is Exhibit 1, a Joint Filing Agreement executed as of the 10th day of September 2026 under Rule 13d-1(k) of the Securities Exchange Act of 1934. Three entities signed it: OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Genesis GP LLC. The latter two each signed through OrbiMed Advisors LLC as managing member, and all three signatures were executed by Carl L. Gordon, identified as a Member of OrbiMed Advisors LLC. The agreement states that each signatory is responsible for the timely filing of the Statement and for the completeness and accuracy of the information concerning itself. OrbiMed Advisors LLC is registered in Delaware under CIK 1055951, with a business address at 601 Lexington Avenue, 54th Floor, New York, NY 10022. For an analyst or reporter, the value here is the identification of who is filing and the structure through which they hold. Braveheart Bio trades on Nasdaq under the ticker BRVE, is incorporated in Delaware, has a fiscal year ending 1231, and is classified under SIC 2834, Pharmaceutical Preparations, with a business address at One Letterman Dr., Bldg. A, Ste. A4-300, San Francisco, CA 94129. EDGAR categorizes it as a non-accelerated filer, a smaller reporting company, and an emerging growth company. What the amendment actually changed is not in the filing excerpt. The number of shares held, the percentage of the class, the dates and prices of any transactions, and the stated purpose of the position are all absent from the text available here, because the excerpt covers only the joint filing exhibit rather than the cover pages and item disclosures. Those figures are in the full document at the source link.